Singapore markets open in 1 hour 27 minutes

Harmony Biosciences Holdings, Inc. (HRMY)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
31.57-0.12 (-0.38%)
At close: 04:00PM EDT
31.57 0.00 (0.00%)
After hours: 04:03PM EDT

Harmony Biosciences Holdings, Inc.

630 West Germantown Pike
Suite 215
Plymouth Meeting, PA 19462
United States
484 539 9800
https://www.harmonybiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees246

Key executives

NameTitlePayExercisedYear born
Mr. Jeffrey S. AroninFounder & Non-Executive Chairman185.67kN/A1968
Dr. Jeffrey M. Dayno M.D.President, CEO & Director1.26MN/A1957
Mr. Jeffrey Dierks M.B.A.Executive VP & Chief Commercial Officer830.75kN/A1972
Mr. Andrew Serafin J.D., M.B.A.Executive VP & Chief Strategy Officer647.42kN/A1975
Dr. Kumar Budur M.D., M.S.Executive VP & Chief Medical Officer760.81kN/AN/A
Mr. David BradshawHead of Technical OperationsN/AN/AN/A
Luis SanayHead of Investor RelationsN/AN/AN/A
Mr. Christian UlrichGeneral Counsel & Corporate SecretaryN/AN/AN/A
Ms. Tricia GloverChief Compliance OfficerN/AN/AN/A
Ms. Audrey Murphy SPHRVice Presidet of Human ResourcesN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Corporate governance

Harmony Biosciences Holdings, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.